Results 41 to 50 of about 3,196 (305)

High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids

open access: yesOncoImmunology, 2019
The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research.
Frank Antony   +12 more
doaj   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch   +13 more
wiley   +1 more source

Ascites

open access: yesThe Korean Journal of Gastroenterology, 2018
Ascites is the most common cause of decompensation in cirrhosis, and 5% to 10% of patients with compensated cirrhosis develop ascites each year. The main factor of ascites formation is renal sodium retention due to activation of the renin-angiotensin-aldosterone system and sympathetic nervous system by the reduced effective volume secondary to ...
openaire   +3 more sources

Ascites matters [PDF]

open access: yesUltrasound, 2016
The excess accumulation of intra-peritoneal fluid, referred to as ascites, is an important clue that points to a significant underlying illness. This may be due to a pathological event within the peritoneal cavity or secondary to an underlying systemic condition.
Velauthan, Rudralingam   +2 more
openaire   +2 more sources

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

open access: yesMolecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric   +10 more
wiley   +1 more source

Urinary ascites

open access: yesIndian Journal of Nephrology, 2012
A middle-aged male presented with abdominal pain and ascites following a fall in alcoholic intoxicated state. Evaluation revealed microscopic hematuria and severe renal failure. Ascitic fluid analysis showed high urea and creatinine values suggesting it to be a urinary ascites. Retrograde cystography confirmed intraperitoneal bladder rupture. Following
Abirami, K.   +3 more
openaire   +2 more sources

Ascite Quilosa (Quiloperitônio) Como Manifestação Inicial de Carcinoma Gástrico

open access: yesRevista Brasileira de Cancerologia, 2001
A ascite quilosa é entidade clínica rara, caracterizada por líquido ascítico de aparência leitosa, com conteúdo de triglicerídeos maior que 1000 mg/dl ou 2 a 8 vezes acima do nível plasmático.
Adriana R. N. Godoy   +2 more
doaj   +1 more source

O que é e como reduzir a ascite em frangos. [PDF]

open access: yes, 2015
Apresentação da ascite; Porque ocorre a ascite; Principais lesões; Principais fatores associados a ocorrência da ascite; Os principais fatores que aceleraram a ascite foram:; Controle da ...
JAENISCH, F. R. F.
core  

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

open access: yesFEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart   +7 more
wiley   +1 more source

Matrix metalloproteinase‐9 regulates cell adhesion and membrane protrusive activity of ovarian cancer cells

open access: yesFEBS Open Bio, EarlyView.
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy